Alcohol and Psoriasis for the Dermatologist: Know, Screen, Intervene

Kearney, Niamh; Kirby, Brian

doi:10.1007/s40257-022-00713-z

Cited by 11 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, given the harmful effects of alcohol in patients with psoriasis, alcohol consumption should be addressed in all patients with psoriasis [ 96 ]. Screening tools, such as AUDIT, AUDIT-Concise (AUDIT-C), and CAGE (Cut, Annoyed, Guilty and Eye) have been validated in psoriasis and represent simple yet effective tools [ 103 ]. Furthermore, interventions encouraging alcohol reduction are extremely valuable in patients with psoriasis, as reduced alcohol consumption can lead to a reduction in psoriasis severity and cardiovascular risk [ 103 ].…”

Section: Pharmacological and Non-pharmacological Interventions Target...mentioning

confidence: 99%

Managing the Patient with Psoriasis and Metabolic Comorbidities

Bellinato,

Maurelli,

Geat

et al. 2024

Am J Clin Dermatol

View full text Add to dashboard Cite

Epidemiological data demonstrate strong associations between psoriasis and metabolic comorbidities, including obesity, hypertension, diabetes mellitus, dyslipidemia, and non-alcoholic fatty liver disease. The presence of metabolic comorbidities significantly influences the selection and effectiveness of pharmacological treatments. Some drugs should be prescribed with caution in patients with metabolic comorbidities because of an increased risk of adverse events, while others could have a reduced effectiveness. The aim of this narrative review is to highlight the challenges that healthcare professionals may face regarding the management of psoriasis in patients with metabolic comorbidities. In the first part of the article, the epidemiological association between psoriasis and metabolic comorbidities and their pathogenetic mechanisms is summarized. The second part describes the efficacy and safety profile of conventional and biologic drugs in patients with selected metabolic comorbidities including obesity, non-alcoholic fatty liver disease/hepatic steatosis, and diabetes. Finally, the role of pharmacological and non-pharmacological interventions, such as diet, alcohol abstinence, physical activity, and smoking avoidance is discussed. In conclusion, the choice of the best approach to manage patients with psoriasis with metabolic comorbidities should encompass both tailored pharmacological and individualized non-pharmacological interventions.

show abstract

Section: Pharmacological and Non-pharmacological Interventions Target...mentioning

confidence: 99%

Managing the Patient with Psoriasis and Metabolic Comorbidities

Bellinato,

Maurelli,

Geat

et al. 2024

Am J Clin Dermatol

View full text Add to dashboard Cite

show abstract

“…The dangerous use of alcohol can cause a chronic disease burden and has a substantial economic and psychological impact [ 29 ]. Excessive consumption of alcohol must be discouraged due to the cumulative effects of alcohol on psoriasis patients at higher risk of liver damage [ 30 ]. Patients with psoriasis used more alcohol than familiar people.…”

Section: Reviewmentioning

confidence: 99%

Psychological Well-Being of Adult Psoriasis Patients: A Narrative Review

Hepat¹,

Chakole²,

Rannaware³

2023

Cureus

View full text Add to dashboard Cite

Psoriasis is a chronic systemic inflammatory condition, and psychiatric comorbidities are common in this condition. It is a non-communicable, autoimmune, and incurable disease. Psoriasis causes an adverse effect and is connected with various psychological symptoms like social isolation, guilt, and embarrassment of a patient. They decrease self-esteem because of depression, anxiety, stress, and substance abuse adults. The prevalence rate of adults is gradually increasing. This study uses various scales to evaluate the level of psoriasis. This study aims to evaluate the level of depression, anxiety, stress, and substance abuse among adult psoriasis patients and to identify the factors affecting psoriasis patients. A detailed search was carried out using essential databases such as PubMed, Google Scholar, and the World Health Organization (WHO) database to search for articles elucidating the same. In total articles, 36 out of 160 are selected. All studies found that psoriasis is at a positive level in that the level of depression and anxiety is moderate to severe, the level of stress is moderate, the level of alcohol abuse is higher, and the level of smoking consumption is ever-increasing. A severe skin condition that impacts the quality of life and psychological health. It has become a public health issue. All the selected articles assessed patients who were highly affected by depression, anxiety, stress, and abuse. They also assessed the various comorbidities related to psoriasis.

show abstract

Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses

Lebwohl,

Armstrong,

Alexis

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Factors such as obesity, alcohol consumption, and tobacco use are associated with both increased psoriasis severity and inadequate response to systemic and biologic therapies. Obesity is linked to chronic inflammation, which can contribute to psoriasis pathogenesis. Fixed-dose therapies may have reduced efficacy in patients with a higher body mass index, while weight-based dosing can increase the burden of drug-specific side effects. Alcohol and nicotine from tobacco have also been shown to stimulate keratinocyte and immune cell proliferation and production of proinflammatory cytokines. While these risk factors are prevalent among patients with moderate-to-severe psoriasis, their influence on treatment outcomes may be overlooked when evaluating therapeutic options. Brodalumab is a fully human interleukin-17 receptor A antagonist approved for the treatment of moderate-to-severe psoriasis. In this review, we describe the lifestyle-related risk factors associated with decreased response to treatment. We further summarize the post hoc analyses of brodalumab in participant subgroups with moderate-to-severe psoriasis and a history of prior biologic failure, obesity, and alcohol or tobacco use from two phase 3 clinical trials (AMAGINE-2 and AMAGINE-3; ClinicalTrials.gov identifiers: NCT01708603 and NCT01708629, respectively). Our review of clinical trial and real-world data suggests that brodalumab is an efficacious and safe treatment option for patients with lifestyle factors that increase the likelihood of treatment failure, allowing them to achieve skin clearance and improve quality of life.

show abstract

Alcohol and Psoriasis for the Dermatologist: Know, Screen, Intervene

Cited by 11 publications

References 55 publications

Managing the Patient with Psoriasis and Metabolic Comorbidities

Managing the Patient with Psoriasis and Metabolic Comorbidities

Psychological Well-Being of Adult Psoriasis Patients: A Narrative Review

Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses

Contact Info

Product

Resources

About